ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent BioPharma (Nasdaq: AVBP), a clinical-stage biopharmaceutical company, has announced plans for a $75 million public offering of common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional 15% of the total securities offered.
The offering will be managed by joint book-running managers Goldman Sachs & Co. LLC, Citigroup, and Guggenheim Securities. ArriVent plans to use the proceeds to support the development of firmonertinib and other pipeline programs, along with working capital and general corporate purposes.
The offering is being conducted through an automatic shelf registration statement on Form S-3ASR filed with the SEC on February 3, 2025. A preliminary prospectus supplement and accompanying base prospectus will be available on the SEC's website.
ArriVent BioPharma (Nasdaq: AVBP), una societ脿 biofarmaceutica in fase clinica, ha annunciato l'intenzione di effettuare un offerta pubblica di 75 milioni di dollari di azioni ordinarie e warrant prefinanziati. La societ脿 conceder脿 inoltre agli underwriter un'opzione di 30 giorni per acquistare fino a un ulteriore 15% dei titoli totali offerti.
L'offerta sar脿 gestita dai co-responsabili del collocamento Goldman Sachs & Co. LLC, Citigroup e Guggenheim Securities. ArriVent intende utilizzare i proventi per sostenere lo sviluppo di firmonertinib e di altri programmi in pipeline, oltre che per capitale circolante e scopi aziendali generali.
L'offerta viene effettuata tramite una dichiarazione di registrazione automatica su modulo S-3ASR depositata presso la SEC il 3 febbraio 2025. Un supplemento al prospetto preliminare e il prospetto base saranno disponibili sul sito web della SEC.
ArriVent BioPharma (Nasdaq: AVBP), una empresa biofarmac茅utica en etapa cl铆nica, ha anunciado planes para una oferta p煤blica de 75 millones de d贸lares de acciones comunes y warrants prefinanciados. La compa帽铆a tambi茅n otorgar谩 a los suscriptores una opci贸n de 30 d铆as para comprar hasta un 15% adicional de los valores totales ofrecidos.
La oferta ser谩 gestionada por los gestores conjuntos Goldman Sachs & Co. LLC, Citigroup y Guggenheim Securities. ArriVent planea usar los ingresos para apoyar el desarrollo de firmonertinib y otros programas en cartera, junto con capital de trabajo y prop贸sitos corporativos generales.
La oferta se realiza mediante una declaraci贸n de registro autom谩tica en el Formulario S-3ASR presentada ante la SEC el 3 de febrero de 2025. Un suplemento preliminar del prospecto y el prospecto base estar谩n disponibles en el sitio web de la SEC.
ArriVent BioPharma (雮橃姢雼�: AVBP)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿滌劀, 7,500毵� 雼煬 攴滊鞚� 氤错喌欤� 氚� 靹犽偐 鞗岆煱韸� 瓿店皽 氇 瓿勴殟鞚� 氚滍憸頄堨姷雼堧嫟. 霕愴暅 須岇偓電� 鞚胳垬鞚鸽摛鞐愱矊 齑� 氚滍枆 歃濌秾鞚� 於旉皜 15%旯岇 30鞚缄皠 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴鞚� 攵�鞐暊 鞓堨爼鞛呺媹雼�.
鞚措矆 瓿惦電� 瓿惦彊 欤缄磤靷澑 Goldman Sachs & Co. LLC, Citigroup, Guggenheim Securities臧� 甏�毽暕雼堧嫟. ArriVent電� 臁半嫭 鞛愱笀鞚� firmonertinib 氚� 旮绊儉 韺岇澊頂勲澕鞚� 頂勲攴鸽灗 臧滊皽, 鞖挫爠鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄頃� 瓿勴殟鞛呺媹雼�.
瓿惦電� 2025雲� 2鞗� 3鞚� SEC鞐� 鞝滌稖霅� Form S-3ASR 鞛愲彊 霌彪 氇呾劯靹滊ゼ 韱淀暣 歆勴枆霅╇媹雼�. 鞓堧箘 歃濌秾 靹る獏靹� 氤挫订靹滌檧 旮半掣 靹る獏靹滊姅 SEC 鞗轨偓鞚错姼鞐愳劀 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
ArriVent BioPharma (Nasdaq : AVBP), une soci茅t茅 biopharmaceutique en phase clinique, a annonc茅 son projet d'offre publique de 75 millions de dollars d'actions ordinaires et de bons de souscription pr茅financ茅s. La soci茅t茅 accordera 茅galement aux souscripteurs une option de 30 jours pour acheter jusqu'脿 15 % suppl茅mentaires des titres totaux offerts.
L'offre sera g茅r茅e par les chefs de file conjoints Goldman Sachs & Co. LLC, Citigroup et Guggenheim Securities. ArriVent pr茅voit d'utiliser les fonds pour soutenir le d茅veloppement du firmonertinib et d'autres programmes en pipeline, ainsi que pour le fonds de roulement et des besoins g茅n茅raux d'entreprise.
L'offre est r茅alis茅e via une d茅claration d'enregistrement automatique sur le formulaire S-3ASR d茅pos茅e aupr猫s de la SEC le 3 f茅vrier 2025. Un suppl茅ment au prospectus pr茅liminaire et le prospectus de base seront disponibles sur le site web de la SEC.
ArriVent BioPharma (Nasdaq: AVBP), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat Pl盲ne f眉r ein 枚ffentliches Angebot von Stammaktien und vorfinanzierten Bezugsrechten im Wert von 75 Millionen US-Dollar bekannt gegeben. Das Unternehmen wird den Underwritern au脽erdem eine 30-t盲gige Option einr盲umen, bis zu 15 % der insgesamt angebotenen Wertpapiere zus盲tzlich zu erwerben.
Das Angebot wird von den gemeinsamen Bookrunnern Goldman Sachs & Co. LLC, Citigroup und Guggenheim Securities geleitet. ArriVent plant, die Erl枚se zur Unterst眉tzung der Entwicklung von Firmonertinib und anderen Pipeline-Programmen sowie f眉r Betriebskapital und allgemeine Unternehmenszwecke zu verwenden.
Das Angebot erfolgt durch eine automatische Shelf-Registrierungserkl盲rung auf Formular S-3ASR, die am 3. Februar 2025 bei der SEC eingereicht wurde. Ein vorl盲ufiger Prospekterg盲nzungsbericht und der zugeh枚rige Basisprospekt werden auf der Website der SEC verf眉gbar sein.
- Potential to raise up to $75 million in fresh capital
- Additional 15% option granted to underwriters could increase total proceeds
- Strong lineup of reputable underwriters including Goldman Sachs, Citigroup, and Guggenheim Securities
- Proceeds will support development of firmonertinib and pipeline programs
- Potential dilution for existing shareholders
- Offering subject to market and other conditions, indicating execution uncertainty
Insights
ArriVent's $75M offering strengthens its cash position to advance firmonertinib and pipeline programs while diluting existing shareholders.
ArriVent BioPharma is pursuing a
The offering structure, featuring both common stock and pre-funded warrants, provides flexibility to different investor types. Pre-funded warrants are particularly attractive to institutional investors who face ownership percentage limitations but want economic exposure to the stock.
The company has secured top-tier investment banks as joint book-running managers, including Goldman Sachs, Citigroup, and Guggenheim Securities, signaling institutional confidence in ArriVent's prospects. These banks bring significant distribution capabilities to ensure offering success.
ArriVent has clearly outlined its use of proceeds: supporting development activities for firmonertinib (their lead asset) and other pipeline programs, plus working capital and general corporate purposes. This indicates a balanced approach between advancing specific clinical programs and maintaining operational stability.
For existing shareholders, this offering will result in dilution of their ownership stake. However, the capital infusion strengthens ArriVent's financial position, potentially extending its operational runway and reducing near-term financing risk. The company's ability to execute this offering within the current market environment will be a key indicator of investor confidence in its clinical development strategy and management team.
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (鈥淎rriVent鈥�) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions,
Goldman Sachs & Co. LLC, Citigroup and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
ArriVent intends to use the net proceeds from the proposed offering, together with its existing cash resources, to support its activities for firmonertinib and its other pipeline programs and for working capital and other general corporate purposes.
An automatic shelf registration statement on Form S-3ASR relating to the securities being sold in this offering was filed with the Securities and Exchange Commission (the 鈥淪EC鈥�) on February 3, 2025 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the聽SEC聽and will be available on the SEC鈥檚 website located at聽, copies of which may be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, or via email: ; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or via telephone: (800) 831-9146; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the聽SEC.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state, province, territory or other jurisdiction.
About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team鈥檚 deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
Cautionary Statement Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding ArriVent鈥檚 business strategies and plans and the proposed public offering and use of proceeds therefrom, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渢arget,鈥� 鈥減otential,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渃ould,鈥� 鈥渟hould,鈥� 鈥渃ontinue鈥� or the negative of these terms or other comparable terminology, which are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond management鈥檚 control. These statements involve risks and uncertainties that may cause ArriVent鈥檚 actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements, as discussed in greater detail in its filings with the SEC, including without limitation, risks and uncertainties related to global economic or market conditions, the satisfaction of customary closing conditions related to the public offering, volatility in the share price of its common stock, changes in its operating plans or funding requirements and the risks and uncertainties described in the section entitled 鈥淩isk Factors鈥� in its annual report on Form 10-K for the year ended December 31, 2024 that was filed with the SEC on March 3, 2025, its quarterly report on Form 10-Q for the quarter ended March 31, 2025 that was filed with the SEC on May 12, 2025 and its subsequent periodic and current reports filed with the SEC. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, ArriVent assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact for Investors & Media
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
FAQ
What is the size of ArriVent BioPharma's (AVBP) proposed public offering?
How will ArriVent (AVBP) use the proceeds from the public offering?
Who are the underwriters for ArriVent's (AVBP) public offering?
When did ArriVent (AVBP) file the shelf registration for this offering?
What types of securities is ArriVent (AVBP) offering in this public offering?
